Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Endpoints Magazine webinar on OV 08 November 23

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Oct 09, 2023 10:07am

136 Views

Post# 35675814

RE:RE:Endpoints Magazine webinar on OV 08 November 23

It's been quite awhile since Endpoints Magazine has shown OV therapies any love. I'm pretty sure I already known what they are going to say. More coverage is always welcomed though.

That Checkpoints and CAR-T have re invigorated interest in OV's as combination therapies. But I'll probably tune in if I have time hopefully. Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023